Alzheimer's disease assessment scale-cognitive 11-item progression model in mild-to-moderate Alzheimer's disease trials of bapineuzumab

INTRODUCTION: The objective of this study was to estimate longitudinal changes in disease progression (measured by Alzheimer's disease assessment scale-cognitive 11-item [ADAS-cog/11] scale) after bapineuzumab treatment and to identify covariates (demographics or baseline characteristics) contr...

Descripción completa

Detalles Bibliográficos
Autores principales: Samtani, Mahesh N., Xu, Steven X., Russu, Alberto, Adedokun, Omoniyi J., Lu, Ming, Ito, Kaori, Corrigan, Brian, Raje, Sangeeta, Brashear, H. Robert, Styren, Scot, Hu, Chuanpu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2015
Materias:
Featured Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5975060/
https://www.ncbi.nlm.nih.gov/pubmed/29854935
http://dx.doi.org/10.1016/j.trci.2015.09.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5975060/
https://www.ncbi.nlm.nih.gov/pubmed/29854935
http://dx.doi.org/10.1016/j.trci.2015.09.001

Ejemplares similares